2023 World Conference on Lung Cancer (Posters)-EP17.03. Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer

EP17.03. Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A pharmacoeconomic analysis was conducted to compare the costs and effectiveness of brigatinib and alectinib as first-line treatments for Chinese patients with ALK-positive non-small cell lung cancer (NSCLC) from a healthcare system perspective. The study found that brigatinib was cost-saving compared to alectinib in terms of total costs. Additionally, brigatinib was found to be economically dominant, with more quality-adjusted life-years (QALYs) gained and lower costs compared to alectinib. Sensitivity analysis showed that drug costs had the greatest influence on the incremental cost-effectiveness ratio (ICER). <br /><br />The study used a partitioned survival model to compare the two treatments over a time horizon of 30 years. Clinical data from the ALTA-1L and ALEX trials were used, and indirect treatment comparison (ITC) data was used to compare brigatinib and alectinib. The analysis accounted for treatment crossover and considered adverse event management costs.<br /><br />The results of the cost-minimization analysis showed that brigatinib was cost-saving compared to alectinib, with a lower total cost. In the cost-effectiveness analysis using specific hazard ratios (HRs), brigatinib was economically dominant, with more QALYs gained and lower costs compared to alectinib. However, the cost-effectiveness results may vary depending on the source of the ITC data.<br /><br />Overall, the study concludes that brigatinib is a cost-saving and economically dominant option for the first-line treatment of ALK-positive advanced NSCLC in China. The findings of this study provide valuable insights for healthcare decision-makers in terms of selecting the most cost-effective treatment option for patients with ALK-positive NSCLC.

Asset Subtitle

Congling Gu

Meta Tag

Speaker Congling Gu

Topic Global Health, Health Services & Health Economics: Health Economics

Keywords

pharmacoeconomic analysis

brigatinib

alectinib

cost-saving

economically dominant

QALYs

incremental cost-effectiveness ratio

ITC data

advanced NSCLC

China